Serious adverse events (6 months · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with hand osteoarthritis
It is very uncertain whether hand exercise changes withdrawal due to adverse events compared with no exercise (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Post‐intervention · adults with stroke
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).
1 finding from 1 review
Adverse events: honey versus SSD · people with burns
It is very uncertain whether honey changes adverse events: honey versus SSD compared with topical antibiotics (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).
1 finding from 1 review
Treatment related adverse events · Patients undergoing any type of surgery under general anaesthesia receiving ACEIs or ARBs perioperatively
1 finding from 1 review
Intervention not reported
Adverse events ‐ endophthalmitis · People undergoing trabeculectomy surgery with glaucoma
1 finding from 1 review
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.05 [1.7, 2.48]
8 studies · 3791 participants
Low
OR 1.51 [1.13, 2]
3 studies · 1196 participants
High
OR 2.6 [2.01, 3.35]
5 studies · 2595 participants
Low
Adverse Events: Infections (All) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Infections (All) compared with no bortezomib (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review